Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc (CRNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Crinetics Pharmaceuticals Inc 6055 Lusk Boulevard San Diego CA 92121 USA

www.crinetics.com Employees: 290 P: 858-450-6464

Description:

Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly, CRN02481 for the treatment of Hyperinsulinemias and CRN01941 for the treatment of Neuroendocrine Tumors which are in clinical stage. Crinetics Pharmaceuticals Inc is based in San Diego, United States.

Key Statistics

Overview:

Market Capitalization, $K 4,970,756
Enterprise Value, $K 4,915,856
Shares Outstanding, K 92,738
Annual Sales, $ 4,010 K
Annual Net Income, $ -214,530 K
Last Quarter Sales, $ 400 K
Last Quarter Net Income, $ -74,050 K
EBIT, $ -277,950 K
EBITDA, $ -283,120 K
60-Month Beta 0.60
% of Insider Shareholders 6.00%
% of Institutional Shareholders 98.51%
Float, K 87,174
% Float 94.00%
Short Volume Ratio 0.79

Growth:

1-Year Return 55.41%
3-Year Return 102.19%
5-Year Return 123.33%
5-Year Revenue Growth 65.02%
5-Year Earnings Growth -65.47%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.96 on 11/12/24
Next Earnings Date N/A
Earnings Per Share ttm -3.78
EPS Growth vs. Prev Qtr -2.13%
EPS Growth vs. Prev Year 4.95%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CRNX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -36.12%
Return-on-Assets % -31.88%
Profit Margin % -5,349.88%
Debt/Equity 0.00
Price/Sales 1,218.79
Price/Cash Flow N/A
Price/Book 5.07
Book Value/Share 10.53
Interest Coverage -2.60
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar